Atopic dermatitis. Interdisciplinary diagnostic and therapeutic recommendations of the Polish Dermatological Society, Polish Society of Allergology, Polish Pediatric Society and Polish Society of Family Medicine. Part II. Systemic treatment and new therapeutic methods

Nowicki, Roman; Trzeciak, Magdalena; Kaczmarski, Maciej; Wilkowska, Aleksandra; Czarnecka‐Operacz, Magdalena; Kowaléwski, Cezary; Rudnicka, Lidia; Kulus, Marek; Mastalerz-Migas, Agnieszka; Peregud-Pogorzelski, Jarosław; Sokołowska‐Wojdyło, Małgorzata; Śpiewak, Radosław; Adamski, Zygmunt; Czuwara, Joanna; Kapińska-Mrowiecka, Monika; Kaszuba, Andrzej; Krasowska, Dorota; Krêcisz, Beata; Majewski, Sławomir; Reich, Adam; Samochocki, Zbigniew; Szepietowski, Jacek C.; Woźniak, Katarzyna

doi:10.5114/dr.2019.89995

Cited by 3 publications

(10 citation statements)

References 33 publications

(137 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Regarding antihistamines, it is worth noting that there is insufficient evidence for their widespread use in treating pruritus in AD. These medications can be used if Dermatology Review/Przegląd Dermatologiczny 2023/5 standard therapy with topical GCs and emollients is insufficient [8][9][10][11].…”

Section: Other Preparations/medications Used By Patients During the S...mentioning

confidence: 99%

“…Besides occlusive substances, they also contain humectants (e.g. glycerin, urea, sorbitol), which are strong moisturizing ingredients, as well as substances that seal the skin barrier -ceramides, cholesterol, or fatty acids [8][9][10][11].…”

mentioning

confidence: 99%

“…In the therapy of AD, emollients are fundamental. They are used not only in monotherapy but also in adjunc-tive therapy for local anti-inflammatory treatment or general treatment [8][9][10][11].…”

mentioning

confidence: 99%

“…A growing understanding of the role of the skin barrier has contributed to the improvement of local moisturizing agents, for example by enriching their composition with certain substances. In recent years, a special range of 'emollients plus' enriched with additional active plant-based substances, such as flavonoids, saponins, non-protein oat extracts, or bacterial lysates from Vitreoscilla filiformis, has been developed [8][9][10][11]. Thanks to the presence of these ingredients, 'emollients plus' have a multifaceted effect.…”

mentioning

confidence: 99%

“…In addition to helping the reconstruction of the skin barrier, they exert a kind of anti-inflammatory effects by inhibiting some pro-inflammatory cytokines and chemokines, have an anti-pruritic effect, and also support innate immunity by activating toll-like receptors and natural antimicrobial peptides. Additionally, they help to restore the homeostasis of the disrupted skin microbiota [8][9][10][11], which appears to play a crucial role in maintaining the function of the skin barrier [12]. Although emollients have a well-established position in the treatment of AD, there is still a lack of studies evaluating their effectiveness in the treatment of other dermatoses that also present with skin dryness.…”

mentioning

confidence: 99%

See 4 more Smart Citations

‘Emollients plus’ with Vitreoscilla filiformis in monotherapy and adjunctive therapy in skin diseases in children

Trzeciak,

Zysk,

Wolańska-Buzalska

2023

View full text Add to dashboard Cite

IntroductIonOne of the most common childhood skin diseases is atopic dermatitis (AD), which affects about 20% of children worldwide [1]. According to the ECAP (Epidemiologia Chorób Alergicznych w Polsce) study data, 3.91% of children suffer from AD in Poland (6-7 years old: 5.34%, 13-14 years old: 4.3%) [2]. The disease is manifested by characteristic skin changes with the morphology of eczema, located in typical areas often visible to others. It is chronic, with periods of exacerbation and remission, and is accompanied by persistent pruritus and sleep disturbances. AD significantly reduces the quality of life of patients and their fami- AbstrActIntroduction: Emollients are topical preparations, the role of which is to maintain or restore epidermal barrier function, proper hydration, and elasticity of the skin. In recent years, a special range of 'emollients plus' enriched with additional active substances has been developed. Objective: To evaluate the effectiveness of emollient preparations with Vitreoscilla filiformis in patients up to 18 years old with skin diseases that present with dryness. Material and methods: From October 2022 to January 2023, an observational study was conducted in Poland. A total of 386 children were recruited for the study, primarily suffering from AD (85.2%) and other skin diseases associated with dryness (23.6%). Results: After 4 weeks of regular usage of emollient products containing Vitreoscilla filiformis in the form of syndet and balm, the severity of the skin disease, dryness, and the surface area of inflammatory changes decreased in 81.8%, 88.0%, and 70.7% of children, respectively. Furthermore, the patient's overall quality of life associated with experiencing symptoms of skin disease significantly improved across all three factors evaluated; reduction in pruritus and severity of daily discomfort were declared by 81.4% and 80.7% of children, respectively. Sleep quality improved in 65.7% of children. An improvement was also observed among patients who solely used the emollient products with Vitreoscilla filiformis without any prescription (RX) treatment. Conclusions:The results indicate that emollient preparations with Vitreoscilla filiformis are effective and well-tolerated by patients with skin diseases that present with dryness. They can be used as monotherapy or as an adjunctive therapy.

show abstract

Section: Other Preparations/medications Used By Patients During the S...mentioning

confidence: 99%

mentioning

confidence: 99%

mentioning

confidence: 99%

mentioning

confidence: 99%

mentioning

confidence: 99%

See 3 more Smart Citations

‘Emollients plus’ with Vitreoscilla filiformis in monotherapy and adjunctive therapy in skin diseases in children

Trzeciak,

Zysk,

Wolańska-Buzalska

2023

View full text Add to dashboard Cite

show abstract

Clinical characteristics of elderly patients with atopic dermatitis — a retrospective observational study

2023

Folia Medica Cracoviensia

View full text Add to dashboard Cite

Atopic dermatitis (AD) is a chronic, recurrent inflammatory dermatosis. The most characteristic symptoms of the disease include itch, eczematous eruptions and excessive dryness of the skin. Elderly patients with AD represent a poorly characterized population because the physiological ageing, possible comorbidity and polypharmacy modify the clinical presentation typically observed in the younger age groups. The aim of the study is to comprehensively assess the clinical characteristics of elderly patients (>60 years old) with AD. Data were collected from 26 AD patients treated in the Department of Dermatology of the University Hospital in Krakow. Late-onset AD with generalized/prurigo lesions was the most predominant phenotype. Skin biopsy was required in 15 (58%) patients in the differential diagnosis process. Allergic rhinitis, a positive family history of atopy and xerosis were associated with a higher number of hospitalizations during the year prior to the last admission (p = 0.034, p = 0.046 and p = 0.036, respectively). Xerosis was more prevalent among subjects with polypharmacy (p = 0.046) and higher serum total IgE concentration (p = 0.048). AD in elderly patients is a new phenotype of the disease that requires careful differential diagnosis. Aged patients with an individual or family history of atopy, due to the increased incidence of severe exacerbations of AD, may benefit from the introduction of proactive therapy.

show abstract

Epidemiology of atopic dermatitis in Poland. Economedica AD

Jahnz-Różyk,

Czarnecka-Operacz,

Lis

et al. 2020

Journal of Health Policy &Amp; Outcomes Research

View full text Add to dashboard Cite

Introduction Atopic dermatitis (AD) is a commonly diagnosed inflammatory disease of the skin, with a chronic and relapsing course, which clinically manifests itself through eczematous skin lesions. The diagnosis is mainly based on the clinical picture of the disease. The goal of this project was to quantify the total population of AD patients in Poland and to make an attempt to determine the clinical profile of the population of patients who are moderately or severely affected by the disease. Methods The Economedica AD project consisted of two parts. The core part of the study, carried out among a representative group of specialists in dermatology and venereology, concerned the information collected from these specialists regarding both the overall health condition of the AD patients, treated by these doctors, as well as the treatment methods used for adult patients with a severe or moderate course of the disease. The second part of the study was an omnibus study, carried out on a representative group of adult Poles, and it mainly included questions concerning the potential presence of clinical AD symptoms. The combination of the two research methods allowed for an extrapolation of the collected data onto the total Polish patient population and to present detailed characteristics of AD patients in Poland. Results On the basis of the omnibus study, the total number of adult AD patients in Poland was estimated to be 705,718 (2.24% of adult Poles). 178,234 adult patients (0.6%), who in the past 12 months experienced a severe or moderate exacerbation of clinical AD symptoms, are currently in the care of dermatologists. Study population, i.e. patients with moderate or severe exacerbation of clinical condition, was also analysed in terms of general course of the disease. As a result of the analysis, estimated number of patients with mild AD was 18,560 (10% of the surveyed population); those with moderate AD: 113,264 (64% of this population), whilst 46,410 (26%) had severe AD. It should be noted that the estimates excluded patients who had only mild disease symptoms in 12 months prior to the study. In the case of 20% of severe AD patients, systemic cyclosporine therapy was initiated within the 12 months prior to the study, while 26% of patients received it within the last 24 months. An analysis of EASI or SCORAD indexes, measured for these two patient groups after the end of cyclosporin therapy, demonstrated the inefficacy of treatment for 47% and 34% of the patients respectively. Despite the clinical indications for such treatment, 54% of the patients underwent systemic cyclosporin therapy in neither of the two analysed periods, mainly due to the patient’s refusal (66%) or contraindications (24%) of the use of cyclosporine (according to the binding guidelines concerning cyclosporine therapy). Conclusions The prevalence of AD among Polish adults was estimated to be 2.24%. The results of the Economedica AD project with respect to the number of adult AD patients are similar to results of the studies carried out both in Poland and in other European countries. A detailed analysis of the subgroup of patients with a severe course of atopic dermatitis has shown a high percentage of patients for whom cyclosporin therapy turned out to be either ineffective (in 47% and 34% of patients treated with CsA in 12 and 24 months prior to the study) or intolerable; this was due to the patient’s refusal (about 66%) or contraindications connected with the patient’s health status or comorbidities (24%).

show abstract

Atopic dermatitis. Interdisciplinary diagnostic and therapeutic recommendations of the Polish Dermatological Society, Polish Society of Allergology, Polish Pediatric Society and Polish Society of Family Medicine. Part II. Systemic treatment and new therapeutic methods

Cited by 3 publications

References 33 publications

‘Emollients plus’ with Vitreoscilla filiformis in monotherapy and adjunctive therapy in skin diseases in children

‘Emollients plus’ with Vitreoscilla filiformis in monotherapy and adjunctive therapy in skin diseases in children

Clinical characteristics of elderly patients with atopic dermatitis — a retrospective observational study

Epidemiology of atopic dermatitis in Poland. Economedica AD

Contact Info

Product

Resources

About